1,2-Dimethyl-5-isopropylbenzimidazol | 69539-86-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1,2-Dimethyl-5-isopropylbenzimidazol
• 英文别名: 5-isopropyl-1,2-dimethyl-1H-benzoimidazole；1,2-dimethyl-5-isopropylbenzimidazole；1,2-dimethyl-5-propan-2-ylbenzimidazole
• CAS: 69539-86-2
• 化学式: C₁₂H₁₆N₂
• 分子量: 188.272
• InChiKey: HOJLUAGXYNZYFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N2 methyl-5-isopropyl-1,2-phenylenediamine 、 乙醇 在 盐酸 、 resultant mixture 、 水 、 crude product 、 环己烷 、 desired product 作用下， 反应 80.0h， 以to give 2.73 g的产率得到1,2-Dimethyl-5-isopropylbenzimidazol
  参考文献：
  名称：

  Substituted benzimidazole compounds and use as herbicides

  摘要：

  1,2-二低烷基-5-支链烷基苯并咪唑及其作为选择性除草剂的用途。

  公开号：

  US04142886A1

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• Epothilone Derivatives
  申请人：Altmann Karl-Heinz

  公开号：US20080114040A1

  公开（公告）日：2008-05-15

  Epothilone derivatives of Formula (I) and their use as a pharmaceutical.

  公式（I）的Epothilone衍生物及其作为药物的用途。
• N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors
  申请人：Kalvista Pharmaceuticals Limited

  公开号：US10781181B2

  公开（公告）日：2020-09-22

  The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.

  本发明提供了式(I)化合物：(I)包含此类化合物的组合物；此类化合物在治疗中的用途（例如在治疗或预防涉及血浆卡利克瑞因活性的疾病或病症中的用途）；以及用此类化合物治疗患者的方法；其中 R5、R6、R7、A、B、U、D、E、W、X、Y 和 Z 如本文所定义。
• N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS
  申请人：KALVISTA PHARMACEUTICALS LIMITED

  公开号：US20170305863A1

  公开（公告）日：2017-10-26

  The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, U, D, E, W, X, Y and Z are as defined herein.
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Novartis AG

  公开号：US20200046845A1

  公开（公告）日：2020-02-13

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.